Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY

Benzinga
2024-09-26

For the year six month period ended June 30

 Note2024



unaudited



£'000
2023



unaudited



£'000
Revenue -298
Research and development costs (2,189)(2,251)
Administrative costs (2,034)(2,291)
Loss from operations (4,223)(4,244)
Finance income3839410
Finance expense3(49)(22)
Loss before tax (3,433)(3,856)
Taxation4125288
Loss for the period attributable to the owners of the parent (3,308)(3,568)
Total comprehensive loss attributable to the owners of the parent (3,308)(3,568)
Loss per share   
Basic and diluted loss per ordinary share – pence5(0.1p)(3.6)p

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10